GGrantIndex
Sort

261,768 grants matching gene therapy

Functional Analysis of Oncogenic Networks in Primary Organoids

$854,573
Calvin J Kuo · Stanford University · U01 · FY2015 · CA

Genetic Epidemiology of Telomere Maintenance and Cancer Etiology

$854,568
Sharon A. Savage · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA

GENE EXPRESSION ANALYSIS OF PROSTATE &LUNG CANCER

$854,560
Dana-Farber Cancer Institute · U01 · FY2000 · CA

Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer

$854,530
Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2021 · CA

Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases

$854,395
Rosh Chandraratna · Io Therapeutics, Inc. · R44 · FY2016 · AI

Regulatory T cells and the tumor microenvironment

$854,385
Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · R35 · FY2024 · CA

Regulation of y-secretase activity by modulatory proteins

$854,379
Yueming Li · Sloan-Kettering Inst Can Research · R01 · FY2022 · AG

RNA modification and innate immune activation in HIV infection

$854,360
Hisashi Akiyama · Boston University Medical Campus · R01 · FY2024 · AI

Omics Analyses of HIV and Substance Use Disorder

$854,351
Vez Repunte-Canonigo · Scripps Research Institute, The · R01 · FY2022 · DA

Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers

$854,326
Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Developing Novel Therapies for High Risk Pediatric Cancers

$854,306
Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

OPTIMIZATION OF DOSING REGIMENS OF SULINDAC IN COMBINATION WITH ERLOTINIB FOR SMALL INTESTINAL AND COLON CANCER PREVENTION

$854,290
Powell Brown · University Of Tx Md Anderson Can Ctr · N01 · FY2019 · CA

Facility and Web-based Approaches to Lifestyle Change in Resistant Hypertension

$854,215
James A. Blumenthal · Duke University · R01 · FY2017 · HL

Zika virus nonstructural protein 5 inhibition of interferon signaling

$854,154
Matthew J Evans · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AI

Clinical Trials with Immunotoxins

$854,104
Ira Pastan · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Analytical Resources Core

$854,035
Nathan A Vandergrift · Duke University · P01 · FY2020 · AI

Biophysical and molecular dialogue of glioma cells and the brain microenvironment

$854,013
Gabriele Bergers · University Of California, San Francisco · U54 · FY2014 · CA

Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells

$854,013
Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Genomic instability in aging and cancer

$854,009
Toren Finkel · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL

Developing RNA therapeutics for rare neurodevelopmental disorders

$853,987
Francesco Lotti · Dayi Therapeutics, Inc. · R42 · FY2025 · HD

Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis

$853,963
Gregory Paul Downey · National Jewish Health · UG3 · FY2018 · TR

Intragraft expression to Predict Future GFR Decline in Kidney Transplantation

$853,920
Mark D Stegall · Mayo Clinic Rochester · U01 · FY2011 · AI

Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir

$853,917
Eric O Johnson · Research Triangle Institute · R61 · FY2020 · DA

Combination Anticancer Nanopreparations of Novel Proapoptotic Drug and siRNA

$853,888
Vladimir P Torchilin · Northeastern University · U54 · FY2010 · CA

Mediators of cancer cell homeostasis: intervention targets common to diverse types of cancer

$853,881
Hartmut Land · University Of Rochester · R35 · FY2021 · CA